Eloxx Pharmaceuticals Stock Net Asset
ELOXDelisted Stock | USD 6.12 0.30 4.67% |
Eloxx Pharmaceuticals fundamentals help investors to digest information that contributes to Eloxx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eloxx Pink Sheet. The fundamental analysis module provides a way to measure Eloxx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eloxx Pharmaceuticals pink sheet.
Eloxx |
Eloxx Pharmaceuticals Company Net Asset Analysis
Eloxx Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Eloxx Pharmaceuticals Net Asset | 21.12 M |
Most of Eloxx Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eloxx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Eloxx Pharmaceuticals has a Net Asset of 21.12 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Eloxx Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eloxx Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eloxx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eloxx Pharmaceuticals by comparing valuation metrics of similar companies.Eloxx Pharmaceuticals is currently under evaluation in net asset category among its peers.
Eloxx Fundamentals
Return On Equity | -6.15 | ||||
Return On Asset | -0.73 | ||||
Current Valuation | 30.28 M | ||||
Shares Outstanding | 2.75 M | ||||
Shares Owned By Insiders | 0.59 % | ||||
Shares Owned By Institutions | 37.06 % | ||||
Number Of Shares Shorted | 21.48 K | ||||
Price To Earning | (7.94) X | ||||
Price To Book | 6.31 X | ||||
EBITDA | (34.42 M) | ||||
Net Income | (36.06 M) | ||||
Cash And Equivalents | 30.05 M | ||||
Cash Per Share | 0.35 X | ||||
Total Debt | 13.38 M | ||||
Current Ratio | 1.62 X | ||||
Book Value Per Share | (7.46) X | ||||
Cash Flow From Operations | (31.84 M) | ||||
Short Ratio | 0.20 X | ||||
Earnings Per Share | (12.93) X | ||||
Target Price | 55.0 | ||||
Number Of Employees | 18 | ||||
Beta | 2.68 | ||||
Market Capitalization | 14.86 M | ||||
Total Asset | 21.12 M | ||||
Retained Earnings | (274.39 M) | ||||
Working Capital | (2.96 M) | ||||
Current Asset | 3.84 M | ||||
Current Liabilities | 840.05 K | ||||
Z Score | -23.07 | ||||
Net Asset | 21.12 M |
About Eloxx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eloxx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eloxx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eloxx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |